Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

resTORbio (TORC) Competitors

resTORbio logo

TORC vs. SAVA, CLYM, MCRB, ANRO, XBIT, IVA, RENB, ENTA, NVCT, and MIST

Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Cassava Sciences (SAVA), Climb Bio (CLYM), Seres Therapeutics (MCRB), Alto Neuroscience (ANRO), XBiotech (XBIT), Inventiva (IVA), Renovaro (RENB), Enanta Pharmaceuticals (ENTA), Nuvectis Pharma (NVCT), and Milestone Pharmaceuticals (MIST). These companies are all part of the "medical" sector.

resTORbio vs.

resTORbio (NASDAQ:TORC) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

resTORbio received 43 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 67.14% of users gave resTORbio an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote.

CompanyUnderperformOutperform
resTORbioOutperform Votes
141
67.14%
Underperform Votes
69
32.86%
Cassava SciencesOutperform Votes
98
65.33%
Underperform Votes
52
34.67%

Cassava Sciences is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41-0.38
Cassava SciencesN/AN/A-$97.22M-$1.38-1.83

Cassava Sciences has a consensus target price of $111.50, indicating a potential upside of 4,307.11%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Cassava Sciences is more favorable than resTORbio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
resTORbio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cassava Sciences
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Cassava Sciences had 23 more articles in the media than resTORbio. MarketBeat recorded 23 mentions for Cassava Sciences and 0 mentions for resTORbio. Cassava Sciences' average media sentiment score of 0.01 beat resTORbio's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
resTORbio Neutral
Cassava Sciences Neutral

46.2% of resTORbio shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 11.8% of resTORbio shares are owned by insiders. Comparatively, 9.0% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

resTORbio has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.99, indicating that its share price is 199% less volatile than the S&P 500.

resTORbio's return on equity of -78.12% beat Cassava Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
Cassava Sciences N/A -88.05%-64.98%

Summary

resTORbio beats Cassava Sciences on 8 of the 15 factors compared between the two stocks.

Get resTORbio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TORC vs. The Competition

MetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$33.47M$6.62B$5.44B$9.25B
Dividend YieldN/A2.94%5.36%3.97%
P/E Ratio-0.519.9089.0617.54
Price / SalesN/A340.051,246.7488.38
Price / CashN/A66.9244.6537.70
Price / Book0.415.185.044.74
Net Income-$82.74M$154.67M$117.90M$224.54M

resTORbio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TORC
resTORbio
N/A$0.92
-2.2%
N/A-61.5%$33.47MN/A-0.51N/A
SAVA
Cassava Sciences
4.3117 of 5 stars
$2.75
+2.2%
$111.50
+3,954.5%
-90.2%$132.30MN/A-1.9930
CLYM
Climb Bio
3.5546 of 5 stars
$1.95
-3.0%
$10.00
+412.8%
N/A$131.08MN/A-0.92N/A
MCRB
Seres Therapeutics
3.4505 of 5 stars
$0.77
+4.4%
$5.08
+562.4%
-27.1%$131.02M$126.33M-3.34330Gap Down
ANRO
Alto Neuroscience
1.5132 of 5 stars
$4.60
+3.7%
$20.00
+335.3%
N/A$123.93MN/A0.00N/AGap Down
XBIT
XBiotech
0.5667 of 5 stars
$3.82
+0.5%
N/A-16.2%$116.45M$4.01M-3.54100
IVA
Inventiva
2.34 of 5 stars
$2.16
flat
$13.25
+513.4%
-43.0%$113.36M$18.91M0.00100News Coverage
Gap Up
RENB
Renovaro
0.7503 of 5 stars
$0.71
-5.7%
N/A-83.5%$112.21MN/A-0.7420Positive News
Gap Up
ENTA
Enanta Pharmaceuticals
4.3735 of 5 stars
$5.25
+8.2%
$17.25
+228.6%
-56.1%$111.27M$67.64M-0.96160
NVCT
Nuvectis Pharma
2.9485 of 5 stars
$5.49
+0.5%
$21.00
+282.5%
-14.4%$106.07MN/A-4.738
MIST
Milestone Pharmaceuticals
2.1346 of 5 stars
$1.98
+1.0%
$13.00
+556.6%
+30.1%$105.59M$1M-2.4430

Related Companies and Tools


This page (NASDAQ:TORC) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners